enGene Holdings Inc ENGN

NAS: ENGN | ISIN: CA29286M1059   16/05/2024
14,19 USD (+4,19%)
(+4,19%)   16/05/2024

2 mei 2024 · enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting · Persbericht

9 april 2024 · /C O R R E C T I O N -- enGene Inc./ · Persbericht

9 april 2024 · enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development · Persbericht

9 april 2024 · enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development · Persbericht

9 april 2024 · engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development · Persbericht

11 maart 2024 · enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress · Persbericht

5 maart 2024 · enGene To Present at the Leerink Partners Global Biopharma Conference · Persbericht

14 februari 2024 · enGene Announces Oversubscribed $200 Million Private Placement Financing · Persbericht

14 februari 2024 · enGene Announces Leadership Succession Plan · Persbericht

30 januari 2024 · enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary · Persbericht

29 januari 2024 · enGene Reports Full Year 2023 Financial Results and Recent Operational Progress · Persbericht

22 december 2023 · enGene Announces Expanded $50 Million Debt Facility with Hercules Capital · Persbericht

19 december 2023 · enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors · Persbericht

Mijn selecties